296 related articles for article (PubMed ID: 20184605)
1. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy.
Shamji MH; Larson D; Eifan A; Scadding GW; Qin T; Lawson K; Sever ML; Macfarlane E; Layhadi JA; Würtzen PA; Parkin RV; Sanda S; Harris KM; Nepom GT; Togias A; Durham SR
J Allergy Clin Immunol; 2021 Oct; 148(4):1061-1071.e11. PubMed ID: 33819508
[TBL] [Abstract][Full Text] [Related]
3. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
4. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
6. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
9. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
[TBL] [Abstract][Full Text] [Related]
10. Synchronous immune alterations mirror clinical response during allergen immunotherapy.
Renand A; Shamji MH; Harris KM; Qin T; Wambre E; Scadding GW; Wurtzen PA; Till SJ; Togias A; Nepom GT; Kwok WW; Durham SR
J Allergy Clin Immunol; 2018 May; 141(5):1750-1760.e1. PubMed ID: 29128670
[TBL] [Abstract][Full Text] [Related]
11. Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy.
Sharif H; Acharya S; Dhondalay GKR; Varricchi G; Krasner-Macleod S; Laisuan W; Switzer A; Lenormand M; Kashe E; Parkin RV; Yi Y; Koc M; Fedina O; Vilà-Nadal G; Marone G; Eifan A; Scadding GW; Fear DJ; Nadeau KC; Durham SR; Shamji MH
J Allergy Clin Immunol; 2021 Feb; 147(2):663-676. PubMed ID: 33160969
[TBL] [Abstract][Full Text] [Related]
12. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
13. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
14. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.
Swamy RS; Reshamwala N; Hunter T; Vissamsetti S; Santos CB; Baroody FM; Hwang PH; Hoyte EG; Garcia MA; Nadeau KC
J Allergy Clin Immunol; 2012 Jul; 130(1):215-24.e7. PubMed ID: 22677046
[TBL] [Abstract][Full Text] [Related]
16. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.
Lima MT; Wilson D; Pitkin L; Roberts A; Nouri-Aria K; Jacobson M; Walker S; Durham S
Clin Exp Allergy; 2002 Apr; 32(4):507-14. PubMed ID: 11972594
[TBL] [Abstract][Full Text] [Related]
17. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation.
Rask C; Brimnes J; Lund K
Scand J Immunol; 2010 Jun; 71(6):403-12. PubMed ID: 20500692
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
19. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
20. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
